Landscape of systemic therapy for ovarian cancer in 2019 : Primary therapy
© 2019 American Cancer Society..
According to the statement from the 5th Ovarian Cancer Consensus Conference in 2015, the primary systemic chemotherapy for advanced ovarian cancer is a combination of paclitaxel plus carboplatin administered every 3 weeks (PCq3w). Optional alternatives include weekly dose-dense paclitaxel, in combination and maintenance therapy with bevacizumab, and intraperitoneal chemotherapy. Since then, in addition to the PCq3w strategy, there has been emerging new evidence, especially for poly(adenosine diphosphate-ribose) polymerase inhibitors. Moreover, there are multiple randomized, phase 3 trials testing the addition of antiangiogenic and/or immune checkpoint inhibitors in this patient population. In this article, current and future perspectives of systemic chemotherapy for advanced ovarian cancer are discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:125 Suppl 24 |
|---|---|
| Enthalten in: |
Cancer - 125 Suppl 24(2019) vom: 15. Dez., Seite 4582-4586 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fujiwara, Keiichi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.05.2020 Date Revised 29.05.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/cncr.32475 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM305649922 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305649922 | ||
| 003 | DE-627 | ||
| 005 | 20231225121636.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cncr.32475 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1018.xml |
| 035 | |a (DE-627)NLM305649922 | ||
| 035 | |a (NLM)31967679 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fujiwara, Keiichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Landscape of systemic therapy for ovarian cancer in 2019 |b Primary therapy |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.05.2020 | ||
| 500 | |a Date Revised 29.05.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 American Cancer Society. | ||
| 520 | |a According to the statement from the 5th Ovarian Cancer Consensus Conference in 2015, the primary systemic chemotherapy for advanced ovarian cancer is a combination of paclitaxel plus carboplatin administered every 3 weeks (PCq3w). Optional alternatives include weekly dose-dense paclitaxel, in combination and maintenance therapy with bevacizumab, and intraperitoneal chemotherapy. Since then, in addition to the PCq3w strategy, there has been emerging new evidence, especially for poly(adenosine diphosphate-ribose) polymerase inhibitors. Moreover, there are multiple randomized, phase 3 trials testing the addition of antiangiogenic and/or immune checkpoint inhibitors in this patient population. In this article, current and future perspectives of systemic chemotherapy for advanced ovarian cancer are discussed | ||
| 650 | 4 | |a Historical Article | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a antiangiogenic | |
| 650 | 4 | |a carboplatin | |
| 650 | 4 | |a intraperitoneal chemotherapy | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a paclitaxel | |
| 650 | 4 | |a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor | |
| 650 | 4 | |a primary chemotherapy | |
| 650 | 7 | |a Antineoplastic Agents, Phytogenic |2 NLM | |
| 650 | 7 | |a Paclitaxel |2 NLM | |
| 650 | 7 | |a P88XT4IS4D |2 NLM | |
| 700 | 1 | |a Hasegawa, Kosei |e verfasserin |4 aut | |
| 700 | 1 | |a Nagao, Shoji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer |d 1948 |g 125 Suppl 24(2019) vom: 15. Dez., Seite 4582-4586 |w (DE-627)NLM000028649 |x 1097-0142 |7 nnns |
| 773 | 1 | 8 | |g volume:125 Suppl 24 |g year:2019 |g day:15 |g month:12 |g pages:4582-4586 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cncr.32475 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 125 Suppl 24 |j 2019 |b 15 |c 12 |h 4582-4586 | ||